Whereas replicative immortality is one of the hallmarks of cancer ([@bib7]), the presence of telomeres create a replication limit in somatic cells. Cancer cells can bypass this limit by reactivating telomerase which is mostly dependent on the amount of telomerase reverse transcriptase (TERT). A high frequency of *TERT* promoter mutations was first discovered in cutaneous melanoma ([@bib11]; [@bib12]) and this was later reported for several different cancers ([@bib15]; [@bib33]). *TERT* mutations enhance the expression of the *TERT* gene by creating *de novo* binding motifs for different transcription factors ([@bib12]). Thus, multiple mechanisms for telomerase reactivation have been described in *TERT* mutant tumours, such as induction of NF-κ*β* signalling and GABPA transcription factors ([@bib2]; [@bib20]; [@bib30]; [@bib1]). There are three previous studies reporting a prognostic significance of *TERT* promoter mutations in primary melanomas ([@bib6]; [@bib26]; [@bib22]), whereas [@bib25] and [@bib5] found no such impact in their series of primary and metastatic melanomas. With the exception of a limited study including six cases of paired primary melanoma and metastatic tumours ([@bib9]), the question whether *TERT* promoter mutation status change during melanoma tumour progression has not been investigated. Further, the protein expression of TERT in cutaneous melanoma is not well described. In a report by [@bib26], TERT expression was not associated with *TERT* mutation or survival, whereas [@bib36] found that TERT protein expression was associated with tumour thickness and ulceration.

In the present study, we investigated whether *TERT* promoter mutations are associated with an aggressive phenotype and reduced survival in a series of nodular melanomas and matched loco-regional metastases. Using a large cohort of matched metastases, we studied whether the mutational status is concordant between primary and metastatic tumours, and whether there are differences between various metastases from the same patients. We also examined TERT protein expression to see whether this correlates with mutation status, clinico-pathologic features and survival.

Material and methods
====================

Patients
--------

This patient series include 255 consecutive cases of primary nodular cutaneous melanomas diagnosed at the Department of Pathology, Haukeland University Hospital (Bergen, Norway) during 1998--2008 ([@bib17]). There was no known history of familial occurrence. During this time period, the sentinel node procedure was not performed in Norway; this patient series therefore lacks complete staging. Cases with sufficient tissue for Sanger sequencing (*n*=194) were thicker, more often ulcerated and had a higher mitotic count when compared with the others (all *P*\<0.05, *χ*^2^-test; data not shown).

In addition, 78 paired tissue specimens from the first appearing local (skin; *n*=26) or regional (lymph nodes; *n*=52) metastatic tumour in this patient series were examined, selecting the largest tumour in case of multiple available lesions.

In 10 cases with discordant and wild-type first metastasis, two different levels from the same metastasis were examined: in five cases, two different formalin-fixed, paraffin-embedded (FFPE) blocks of tumour tissue from the same metastasis were examined, and in five cases, tumour tissue from two different levels of the same FFPE block was examined. In 4 of these 10 cases, subsequently appearing multiple metastases were examined (*n*=6). These subsequent metastases were also loco-regional metastases.

Median age at diagnosis was 70 years and median thickness of the primary tumour was 3.6 mm (range 0.7--29.0 mm). Complete information on patient survival, time and cause of death was available in all 255 cases. Last date of follow-up regarding survival was 31 December 2014 and median follow-up time for survivors was 115 months (range 72--203 months). During the follow-up period, 88 patients (35%) died of malignant melanoma and 76 (30%) died of other causes. A summary of patient characteristics is given in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}.

The Norwegian Data Inspectorate and the Regional Committee for Ethics in Research (Health Region III; 178.05) have approved this project. The study was performed in accordance with the Declaration of Helsinki Principles.

Clinico-pathologic variables
----------------------------

Clinical data and histologic variables were included: date of histologic diagnosis, sex, age at diagnosis, tumour anatomic site, tumour thickness according to Breslow ([@bib3]), level of invasion according to Clark ([@bib4]), mitotic count, the mitotic marker PHH3 ([@bib17]), microscopic tumour ulceration ([@bib17]) and tumour necrosis ([@bib18]). In addition, previously recorded data on *BRAF* mutation status was included ([@bib13]).

Tissue microarray
-----------------

The tissue microarray (TMA) technique has been described and validated in several studies ([@bib16]; [@bib24]; [@bib32]). Three tissue cylinders (diameter 1.0 mm) from representative tumour areas identified on H&E-stained slides, such as the supra-basal area of the primary melanomas, were punched from archival blocks and mounted into a recipient paraffin block using a custom made precision instrument (Beecher Instruments, Silver Spring, MD, USA). Sections of the resulting TMA blocks (5 μm) were made by standard technique.

Immunohistochemistry
--------------------

Immunohistochemical staining was performed on 5 μm TMA sections. Sufficient tumour tissue for immunohistochemistry was available in 248 of the 255 primary melanoma cases and 68 of the 78 paired loco-regional metastatic melanomas. For detection of TERT expression, the slides were dewaxed with xylene/ethanol before microwave antigen retrieval for 30 min in Target Retrieval Solution (DAKO 1699, Glostrup, Denmark) (pH 6). Endogenous peroxidase activity was prevented by treating the slides with peroxidase block (DAKO S2001) for 8 min. The slides were incubated with an anti-telomerase catalytic subunit (hTERT) polyclonal rabbit antibody (dilution 1:125) (catalogue number 600-401-252) (Rockland, Limerick, PA, USA) overnight at 4 °C. The reliability of this antibody has been validated in the study by [@bib35]. The staining procedure was performed using the anti-rabbit EnVision labelled polymer method (DAKO K4011) with 3-amino-9-ethylcarbazole (DAKO K3469) as substrate chromogen. Brief counterstaining was performed with haematoxylin (DAKO S2020). Negative controls were obtained by omitting the primary antibody.

Evaluation of staining
----------------------

Expression of hTERT was characterised by cytoplasmic staining of melanoma cells. The staining intensity was recorded as either negative, weak, moderate or strong (0--3) and proportion of tumour cells stained was recorded as 1 (\<10%), 2 (10--50%) or 3 (\>50%). A staining index (SI) was calculated as the product of intensity and proportion scores ([@bib31]). A subset of cases (*n*=69) was scored blindly by two observers (EH and RGL) showing good inter-observer agreement (*κ*=0.77, *P*\<0.01). Evaluation of the cases was done blinded for patient characteristics and outcome.

DNA extraction
--------------

In primary melanoma and metastases, the whole circumference of the tumour area was identified and marked by the pathologist (LAA) on H&E-stained slides. Marked tumour tissue was manually dissected from five subsequent 10 μm sections of FFPE tissue. DNA was extracted using the QIAmp DNA FFPE Tissue Kit (Qiagen 56404, Hilden, Germany) for the first 130 primary melanoma cases and the E.Z.N.A tissue DNA kit (Omega Biotek D3396, Norcross, GA, USA) for the remaining cases (with no significant difference in mutation frequency) and for the metastatic tumour cases. The DNA concentration was determined by the NanoDrop Spectrophotometer.

Sanger sequencing
-----------------

PCR amplification was performed using the TaKaRa LATaq DNA polymerase (Takara Bio, Mountain View, CA, USA) or AmpliTaq Gold PCR Master Mix (Applied Biosystems, Foster City, CA, USA). PCR amplification of the *TERT* promoter region was performed using primers hTERT_short_F 5′-CAGCGCTGCCTGAAACTC-3′ and hTERT_short_R 5′-GTCCTGCCCCTTCACCTT-3′ (163 bp product) as described by [@bib11]. PCR products were enzymatically treated by Illustra ExoProStar 1-Step before sequenced in both directions using the BigDye Terminator Cycle Sequencing Kit version 1.1 (Applied Biosystems). The sequence reactions were analysed on the Applied Biosystems 3500xL Genetic Analyzer using Sequencing Analysis software, version 6 (Applied Biosystems) and the electropherograms were examined manually.

Statistics
----------

Statistical analyses were performed using the IBM Statistical Package for the Social Sciences version 23 (IBM Corp., Armonk, NY, USA). Associations between categorical variables were assessed by the Pearson's *χ*^2^-test. Comparison of two or more continuous variables not following the normal distribution was performed using the Mann--Whitney's *U*-test or Kruskal--Wallis tests. κ statistics was used in analyses of inter-observer agreement of categorical data.

Univariate analyses of time to death due to malignant melanoma were performed using the product-limit procedure (Kaplan--Meier method) with the log-rank test for differences, and with date of histological diagnosis as the starting point for analyses of primary melanomas and date of first metastasis as the starting point for analyses of metastatic melanomas. Patients who died of other causes were censored at the date of death. The influence of co-variates on patient survival was analysed by the proportional hazards method, and tested by the likelihood ratio (lratio) test. All results were considered significant if *P*\<0.05.

Results
=======

Telomerase reverse transcriptase promoter mutation status
---------------------------------------------------------

*TERT* promoter mutation status was assessed by Sanger sequencing in cases with sufficient tissue (primary melanomas; *n*=194, metastatic melanomas; *n*=72). One hundred and thirty-one (68%) of the primary melanomas were mutation positive; 45% had the −124 C\>T mutation and 44% showed −146 C\>T; 11% had less frequent mutations (−138/−139 CC\>TT and --124/−125 CC\>TT). Forty-six (64%) of the first appearing metastases were mutation positive; of these, 39% harboured the --124 C\>T, 54% showed --146 C\>T and 7% had −138/−139 CC\>TT ([Table 1](#tbl1){ref-type="table"} and [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}).

There was sufficient tumour tissue in both the primary and matched metastatic lesions in 58 cases. Of these, *TERT* promoter mutation was present in 41 (71%) of the primary tumours and in 35 (60%) of the corresponding first appearing metastases. Regarding concordance, 10 cases (17%) had a *TERT* promoter mutation in the primary tumour but not in the paired metastases, whereas 4 cases (7%) had a *TERT* promoter mutation in the metastatic tumour, but not in the primary tumour. Altogether, 14 cases (24%) had discordant status in terms of presence versus absence of *TERT* mutation, among which 71% did not show a mutation in the metastatic tumour ([Table 2](#tbl2){ref-type="table"}).

To investigate potential tumour heterogeneity, *TERT* mutation status was re-analysed in the 10 discordant cases with the absence of mutations in the first appearing metastases and a mutation-positive primary tumour, now including a different area of the metastatic lesion. In addition, among these 10 discordant cases, mutations were also analysed in subsequent metastases, which occurred in four cases. Altogether, in 6 of the 10 cases, *TERT* wild type was confirmed when re-analysing different regions of the same metastasis, whereas in four cases a *TERT* mutation was present. Among four of the 10 cases with subsequent metastases, 3 such cases were *TERT* mutation positive, whereas 1 case had a wild-type tumour. When looking at all metastatic lesions, including subsequent tumours, 6 out of 10 cases had a *TERT* mutation and 4 out of 10 cases were *TERT* wild type ([Table 3](#tbl3){ref-type="table"}).

Telomerase reverse transcriptase promoter mutation status and associations with clinico-pathologic features and BRAF mutations
------------------------------------------------------------------------------------------------------------------------------

Among *TERT* promoter-mutated primary melanomas, there were trends for increased tumour thickness (*P*=0.10, Mann--Whitney test), increased PHH3 count for proliferation (*P*=0.08, Mann--Whitney test) and higher patient age (*P*=0.098, Mann--Whitney test) ([Table 4](#tbl4){ref-type="table"}), whereas there were no associations between mutation and level of invasion according to Clark, tumour ulceration, tumour necrosis or anatomic location.

*TERT* mutations tended to be more frequent in *BRAF* wild type than *BRAF*-*V600E*-mutated melanomas, although not significant. *TERT-*mutated cases (66%) were *BRAF* wild type, whereas co-existence of the two mutations was present in 23% of the primary melanomas ([Table 4](#tbl4){ref-type="table"}).

Survival analyses according to *TERT* promoter mutations
--------------------------------------------------------

*TERT* mutation in the primary tumours (*n*=194) was not associated with reduced recurrence-free survival, measured as time from diagnosis of the primary tumour to first metastasis or melanoma-specific survival ([Figure 1](#fig1){ref-type="fig"}). In addition, there was no difference in survival between the different *TERT* promoter mutations. When analysing the combined *TERT/BRAF* mutation status, there was a trend for reduced survival among cases with co-existing *TERT* and *BRAF* mutations compared with all others (*P*=0.098, log-rank test) ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). In the metastatic setting (*n*=72), there was a trend for reduced melanoma-specific survival in *TERT* wild-type melanoma (*P*=0.09, log-rank test) ([Figure 1](#fig1){ref-type="fig"}). Finally, combinations of *TERT* mutation status among paired primary and metastatic lesions (*n*=58) showed no association with survival ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}).

Telomerase reverse transcriptase protein expression and association with TERT promoter mutation, clinico-pathologic features and survival
-----------------------------------------------------------------------------------------------------------------------------------------

Immunohistochemical staining obtained with the TERT antibody was assessed in 248 primary melanomas and 68 paired loco-regional metastases. The staining was cytoplasmic and generally homogenous, and differences in staining intensity between tumour areas (heterogeneity) were rarely observed. Telomerase reverse transcriptase expression was categorised according to SI as either negative or positive with cut-off values based on the median (SI 4) in primary melanomas. Telomerase reverse transcriptase expression was positive in 44% of primary melanomas (*n*=108) and 16% of loco-regional metastatic melanomas (*n*=11) ([Figure 2](#fig2){ref-type="fig"}).

Positive TERT expression in primary melanomas was associated with increased tumour thickness (*P*=0.009, Mann--Whitney's test), with a trend for presence of tumour necrosis (*P*=0.056, *χ*^2^-test) ([Table 5](#tbl5){ref-type="table"}). Further, positive TERT expression in primary melanoma was associated with reduced survival in univariate analysis (*P*=0.048, log-rank test) ([Figure 3](#fig3){ref-type="fig"}), with borderline significance in multivariate analysis (*P*=0.087) ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). There was a trend for association of positive TERT expression with reduced survival in metastatic melanoma (*P*=0.067, log-rank test) ([Figure 3](#fig3){ref-type="fig"}).

There was no significant correlation between *TERT* mutation status and TERT protein expression in primary (*P*=0.31, Mann--Whitney test) or metastatic tumours (*P*=0.90, Mann--Whitney test). Among primary tumours with positive TERT protein expression, 30% (*n*=27) did not have a *TERT* promoter mutation ([Table 5](#tbl5){ref-type="table"}).

There was sufficient tumour tissue in matched primary and metastatic lesions in 66 cases. Among these, TERT expression was positive in 36 (55%) of the primary tumours, compared with 18 (27%) of the metastatic tumours. Twenty-three cases (35%) were TERT expression positive in the primary tumour but negative in the paired metastatic lesion; five cases (8%) were TERT expression positive in the metastatic tumour, but not in the matched primary tumour. Altogether, TERT expression status was discordant in 28 cases (42%) ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}).

Discussion
==========

We here found that 68% of the primary melanoma and 64% of loco-regional metastases harbored *TERT* promoter mutations. This frequency in primary tumours is relatively high compared to previous studies ([@bib6]; [@bib9]; [@bib26]; [@bib22], [@bib23]). As a possible explanation, *TERT* mutations are reported to be more frequent in nodular melanomas compared with other subtypes ([@bib9]; [@bib21]; [@bib22]). In addition, our series has a rather high median age, and *TERT* mutations have been associated with increased age at diagnosis ([@bib9]; [@bib22]).

A possible explanation for the lack of prognostic impact in primary nodular and loco-regional metastatic melanomas might be that *TERT* mutations have lost their impact at these advanced stages of tumour progression, and that mutations in other genes are important for further progress, like *CDKN2A*, *PTEN* or *TP53* ([@bib10]; [@bib29]; [@bib8]). In support of this hypothesis, a relatively high *TERT* mutation discordance rate was found in paired primary and metastatic lesions, with 71% of discordant cases being *TERT* mutation negative in metastases. This might indicate that, in a subgroup of the tumours, *TERT* promoter mutation is not required for further progression at the stage of loco-regional metastasis.

To elucidate the possibility that the observed discordancy could be due to tumour heterogeneity, we re-analysed *TERT* mutation status in the ten discordant and wild-type metastases in other regions of the tumour and we also analysed *TERT* mutation status in subsequent metastases among these discordant cases. Thus, we found that six of the 10 first appearing metastases were *TERT* wildtype when re-tested in other intra-tumour regions, whereas 4 of 10 metastases were *TERT* mutated when re-analysed. Among four cases with subsequent metastases, three lesions were *TERT* mutated, whereas one case was wild type. This indicates that both intra- and inter-tumoural heterogeneity of *TERT* mutation status appear to be present in cutaneous melanoma.

Furthermore, we found no correlation between *TERT* mutations and increased TERT protein expression. Among primary melanomas with positive TERT protein expression, 30% did not have a *TERT* promoter mutation. There are several proposed alternative mechanisms of telomerase activation, which could explain this observation, such as alternative splicing of *TERT* mRNA ([@bib34]) and epigenetic alterations such as DNA methylation ([@bib19]; [@bib27]). In a recent study of melanomas in adolesents and young adults, methylation of the *TERT* promoter, but not *TERT* promoter mutations, was associated with reduced recurrence-free survival ([@bib28]).

We studied, for the first time using a melanoma cohort of sufficient size, *TERT* mutations and TERT protein expression status in paired primary and metastatic lesions, finding a high degree of discordancy for both. This supports the theory of melanoma being a complex and heterogenous disease, with tumours also evolving over time ([@bib14]; [@bib29]). A possible explanation is that both *TERT* promoter mutated and wildtype tumour cells are present in the primary melanoma, as indicated by our findings, both clones capable of giving rise to metastases. The frequency and significance of discordancy should be further studied.

In conclusion, we found that *TERT* promoter mutations are highly frequent in both primary and metastatic melanomas, which could be due to the nodular subtype and old patient age in our cohort. Importantly, we report that the mutation status changed in 24% of the cases during tumour progression. However we found no prognostic impact of *TERT* mutations. As a novel finding, TERT protein expression was significantly associated with increased tumour thickness and reduced patient survival, but was not related to *TERT* promoter mutation status.
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![**Survival curves by *TERT* promoter mutation status in primary melanoma (*n*=194) and loco-regional metastases (*n*=72) (Kaplan--Meier method, log-rank significance test).**](bjc2017384f1){#fig1}

![**Immunohistochemical staining.** Immunohistochemical staining showing two pairs (**A**--**D**) with discordant TERT expression: TERT-positive primary melanoma (**A**) with a TERT-negative metastasis (**B**), TERT-negative primary melanoma (**C**) with a TERT-positive metastasis (**D**).](bjc2017384f2){#fig2}

![**Survival curves by TERT protein expression in primary melanoma (*n*=248) and loco-regional metastases (*n*=68) (Kaplan--Meier method, log-rank significance test).**](bjc2017384f3){#fig3}

###### *TERT* mutation frequencies

                              **Primary melanoma (*****n*****=194)**   **Metastatic melanoma (*****n*****=72)**
  -------------------------- ---------------------------------------- ------------------------------------------
  **TERT**                                                            
  Wild type (*n*)                            63 (32%)                                  26 (36%)
  Mutation (*n*)                            131 (68%)                                  46 (64%)
  --124 C\>T (*n*)                           59 (45%)                                  18 (39%)
  --146 C\>T (*n*)                           58 (44%)                                  25 (54%)
  --138/--139 CC\>TT (*n*)                   12 (9%)                                    3 (7%)
  --124/--125 CC\>TT (*n*)                    2 (2%)                                    0 (0%)

Abbreviation: TERT=telomerase reverse transcriptase.

###### *TERT* promoter mutation status in paired samples of primary tumours and metastases (*n*=58)

                                       **Primary** t**umour**                          
  ----------------------------------- ------------------------ ------------ ---------- ------------
  Loco-regional metastasis                                                                   
  *TERT* --146 C\>T (*n*=18)                 13 (22 4%)          3 (5.2%)     0 (0%)     2 (3.4%)
  *TERT* --124 C\>T (*n*=14)                  2 (3.4%)          10 (17.2%)    0 (0%)     2 (3.4%)
  *TERT* --138/--139 CC\>TT (*n*=3)            0 (0%)             0 (0%)     3 (5.2%)     0 (%)
  *TERT* wild type (*n*=23)                   4 (6.9%)           4 (6.9%)    2 (3.4%)   13 (22.4%)

###### *TERT* mutation status in 10 discordant cases with wild type first metastasis and a mutation-positive primary tumour

  **Case**                          **First appearing metastasis (different part of tumour)**   **Second appearing metastasis**   **Third appearing metastasis**                                                    
  -------------------------------- ----------------------------------------------------------- --------------------------------- -------------------------------- ---------- ------ -------------- --------- ------ --------------
  558[d](#t3-fn5){ref-type="fn"}                             Mutated                                      Lymph node                       Metachronous            Mutated    Skin   Synchronous    Mutated   Skin   Synchronous
  567[e](#t3-fn6){ref-type="fn"}                            Wild type                                        Skin                          Metachronous            Mutated    Skin   Metachronous                          
  569[e](#t3-fn6){ref-type="fn"}                             Mutated                                         Skin                          Metachronous                                                                    
  582[e](#t3-fn6){ref-type="fn"}                            Wild type                                     Lymph Node                       Synchronous                                                                     
  615[d](#t3-fn5){ref-type="fn"}                             Mutated                                         Skin                          Metachronous                                                                    
  641[d](#t3-fn5){ref-type="fn"}                            Wild type                                     Lymph Node                       Metachronous                                                                    
  668[e](#t3-fn6){ref-type="fn"}                            Wild type                                        Skin                          Metachronous            Wildtype   Skin   Metachronous                          
  675[d](#t3-fn5){ref-type="fn"}                            Wild type                                        Skin                          Synchronous                                                                     
  699[e](#t3-fn6){ref-type="fn"}                            Wild type                                     Lymph Node                       Synchronous             Mutated    Skin   Metachronous   Mutated   Skin   Metachronous
  729[d](#t3-fn5){ref-type="fn"}                             Mutated                                      Lymph Node                       Metachronous                                                                    

Abbreviation: FFPE=formalin-fixed paraffin-embedded.

Compared with primary tumour.

Compared with first appearing metastasis.

Compared with second appearing metastasis.

Tumour tissue from another FFPE block of the tumour than originally tested.

Tumour tissue from a deeper level of the tumour in the same FFPE block as originally tested.

###### *TERT* promoter mutation and associations with clinico-pathologic features and *BRAF* mutation in primary melanoma (*n*=194)

                                                  ***TERT*** **promoter status**             
  ---------------------------------------------- -------------------------------- ---------- ---------------------------------
  Tumour thickness (mm) median                                 3.7                   4.7      0.10[a](#t4-fn2){ref-type="fn"}
  Ulceration[b](#t4-fn3){ref-type="fn"}                                                        NS[c](#t4-fn4){ref-type="fn"}
   Absent (*n*)                                              30 (48%)              51 (39%)                   
   Present (*n*)                                             32 (52%)              79 (61%)                   
  Mitotic count (no/mm^2^) median                              4,7                   6,6      0.18[a](#t4-fn2){ref-type="fn"}
  PHH3 (no/mm^2)^ median                                        33                    44      0.08[a](#t4-fn2){ref-type="fn"}
  Tumour necrosis                                                                              NS[c](#t4-fn4){ref-type="fn"}
   Absent (*n*)                                              46 (73%)              92 (70%)                   
   Present (*n*)                                             17 (27%)              39 (30%)                   
  Age (years) median                                            67                    73      0.10[a](#t4-fn2){ref-type="fn"}
  Gender                                                                                       NS[c](#t4-fn4){ref-type="fn"}
   Female (*n*)                                              32 (51%)              53 (40%)                   
   Male (*n*)                                                31 (49%)              78 (60%)                   
  Anatomic location[d](#t4-fn5){ref-type="fn"}                                                 NS[c](#t4-fn4){ref-type="fn"}
   Truncus (*n*)                                             17 (27%)              39 (30%)                   
   Other sites (*n*)                                         45 (73%)              90 (70%)                   
  *BRAF* status[e](#t4-fn6){ref-type="fn"}                                                     NS[c](#t4-fn4){ref-type="fn"}
   WT (*n*)                                                  32 (56%)              80 (66%)                   
   V600E (*n*)                                               25 (44%)              41 (34%)                   

Abbreviations: NS=not significant; WT=wild type.

Mann--Whitney *U*-test.

Two missing cases.

*χ*^2^-test.

Three missing cases.

16 Missing cases due to insufficient tissue.

###### TERT protein expression and associations with clinico-pathologic features and *TERT* promoter mutation in primary melanoma (*n*=248)

                                                       **TERT protein expression**[a](#t5-fn2){ref-type="fn"}             
  --------------------------------------------------- -------------------------------------------------------- ---------- ----------------------------------
  Tumour thickness (mm) Median                                                  3,1                               4,0      0.009[b](#t5-fn3){ref-type="fn"}
  Ulceration[c](#t5-fn4){ref-type="fn"}                                                                                     NS[d](#t5-fn5){ref-type="fn"}
   Absent (*n*)                                                               68 (49%)                          47 (44%)                   
   Present (*n*)                                                              70 (51%)                          59 (58%)                   
  Mitotic count (no/mm^2^)                                                                                                  NS[d](#t5-fn5){ref-type="fn"}
  median                                                                        4,0                               4,3                      
  Tumour necrosis                                                                                                          0.06[d](#t5-fn5){ref-type="fn"}
   Absent (*n*)                                                              112 (80%)                          75 (69%)                   
   Present (*n*)                                                              28 (20%)                          33 (31%)                   
  Age (years) median                                                             70                                71       NS[b](#t5-fn3){ref-type="fn"}
  Gender                                                                                                                    NS[d](#t5-fn5){ref-type="fn"}
   Female (*n*)                                                               61 (44%)                          51 (47%)                   
   Male (*n*)                                                                 79 (56%)                          57 (53%)                   
  Anatomic location[c](#t5-fn4){ref-type="fn"}                                                                              NS[d](#t5-fn5){ref-type="fn"}
   Truncus (*n*)                                                              41 (29%)                          35 (33%)                   
   Other sites (*n*)                                                          99 (71%)                          70 (67%)                   
  *TERT* promoter status[e](#t5-fn6){ref-type="fn"}                                                                         NS[d](#t5-fn5){ref-type="fn"}
   WT (*n*)                                                                   36 (35%)                          27 (30%)                   
   Mutation (*n*)                                                             67 (65%)                          63 (70%)                   

Abbreviations: NS=not significant; SI=staining index; TERT=telomerase reverse transcriptase; WT=wild type.

Cut-off point SI median quartile.

Mann--Whitney test.

Three missing cases.

*χ*^2^-test.

55 Missing cases.
